Document Detail

Growth differentiation factor 15: An additional diagnostic tool for the risk stratification of developing heart failure in patients with operated congenital heart defects?
MedLine Citation:
PMID:  21742099     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND: Many young adults who have congenital heart defects develop heart failure despite corrective surgeries. Growth differentiation factor 15 (GDF-15) has an established role as a marker for risk stratification and mortality both in patients after acute myocardial infarction and in patients with heart failure. Our aim was to establish a role for GDF-15 for monitoring heart failure in operated congenital heart defects (ACHD). This potential biomarker was validated through comparison with maximal oxygen uptake (VO(2max)) and to another biomarker, N-terminal pro-brain natriuretic peptide (NT-proBNP).
METHODS: A total of 317 ACHD patients (129 females) with an average age of 26.5 ± 8.5 years (mean ± SD) enrolled in the study. We studied the relation between GDF-15 and NT-proBNP and VO(2max%) (percent predicted for age and gender). The cutoffs for the groups were as follows: NT-proBNP <100, 100 to 300, and >300 pg/mL; VO(2max%) <65%, 65% to 85%, and >85% of predicted normal.
RESULTS: Significant differences in mean GDF-15 levels were found between the NT-proBNP <100 and NT-proBNP >300 groups, as well as between the 100 to 300 and the >300 groups. For VO(2max%), significant differences were found in GDF-15 levels between <65% and >85% and between <65% and 65% to 85%, respectively. The lowest mean GDF-15 was found in groups with NT-proBNP <100 pg/mL and VO(2max%) >85%. The highest mean GDF-15 was found in the groups with NT-proBNP >300 pg/mL and VO(2max%) <65%. A subgroup analysis, including 82 patients with operated tetralogy of Fallot, showed that patients in the New York Heart Association I class have significantly lower NT-proBNP and GDF-15 level and markedly higher VO(2max) compared with the patients in higher New York Heart Association class.
CONCLUSION: Growth differentiation factor 15 might be used as a surrogate marker for latent heart failure and could help to identify patients with ACHD who are at risk for developing heart failure, even if they are clinically asymptomatic.
Kambiz Norozi; Reiner Buchhorn; Abeer Yasin; Siegfried Geyer; Lutz Binder; Jamie A Seabrook; Armin Wessel
Related Documents :
22411359 - Cost-effectiveness of cytochrome p450 2c19 genotype screening for selection of antiplat...
22904109 - Neutrophil-lymphocyte ratio as a predictor of major adverse cardiac events among diabet...
9731689 - Left ventricular dilatation after myocardial infarction: ace inhibitors, beta-blockers,...
21604919 - Endothelial dysfunction predicts clinical restenosis after percutaneous coronary interv...
6108879 - A case report of maternal death associated with betamimetics and betamethasone administ...
8576789 - Update on the use of angiotensin converting enzyme inhibitors and calcium antagonists i...
7977819 - Activation of atp-sensitive potassium channels lowers threshold for ischemic preconditi...
23315159 - An 8-year single-centre experience of cardiac resynchronisation therapy: procedural suc...
19185649 - Predictive factors for in-stent late loss and coronary lesion progression in patients w...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American heart journal     Volume:  162     ISSN:  1097-6744     ISO Abbreviation:  Am. Heart J.     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-07-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  131-5     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2011 Mosby, Inc. All rights reserved.
Department of Paediatrics, London Health Sciences Centre, University of Western Ontario, Canada; Departments of Paediatric Cardiology and Intensive Care Medicine, Medical School, Hannover, Germany; Children's Health Research Institute, London, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Practice variability and outcomes of coil embolization of aortopulmonary collaterals before Fontan c...
Next Document:  Resting cardiac energy metabolism is inversely associated with heart rate in healthy young adult men...